Journal
ONCOGENE
Volume 23, Issue 23, Pages 4173-4176Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1207571
Keywords
p21; E2F-1; cell cycle; cdk2
Funding
- NCI NIH HHS [CA91146-01A1] Funding Source: Medline
- NIDDK NIH HHS [R01 DK044525-10, R01 DK044525, DK48836] Funding Source: Medline
Ask authors/readers for more resources
p21 is a potent inhibitor of cyclin-dependent kinases capable of arresting cell cycle progression. p21 is primarily regulated at the transcriptional level by several transcription factors, including p53. Previously, we reported that certain members of the E2F family of transcription factors may activate p21 transcription via a p53-independent mechanism. To further elucidate the consequences of E2F-1-regulated induction of p21, we developed cell lines with a tamoxifen-dependent form of E2F-1. We confirmed direct interaction of E2F-1 with the proximal region of the p21 promoter. Interestingly, elevated E2F-1 activity was sufficient to arrest a substantial subset of cells in S phase and this effect was correlated to and dependent on the induction of p21 protein. Since E2F proteins control genes required for cell cycle progression and are activated by various oncogenic events, we believe that the p21-dependent arrest described in this report represents an additional mechanism that guards against unrestricted cell proliferation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available